Drug Profile
Interferon gamma inhalation - RELIEF THERAPEUTICS Holding
Latest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Antibacterials; Antineoplastics; Antivirals; Interferons; Lymphokines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Idiopathic pulmonary fibrosis
Highest Development Phases
- Discontinued Idiopathic pulmonary fibrosis
Most Recent Events
- 01 Jul 2022 Discontinued - Phase-II for Idiopathic pulmonary fibrosis, before July 2022 (Inhalation) (RELIEF THERAPEUTICS pipeline, July 2022)
- 19 Sep 2016 Interferon gamma inhalation is available for licensing in USA, Europe as of 19 Sep 2016.
- 19 Sep 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis (Inhalation)